New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

In a new study, the drug, deucravacitinib, proved to be a safe and more effective treatment for cutaneous lupus erythematosus disease (CLE, lupus skin disease) than two other commonly used therapies, ...

In light of litifilimab recently receiving FDA Breakthrough Therapy Designation for CLE, we spoke with experts to discuss diagnostic and treatment gaps in disease management.

Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant improvement in their symptoms after a year on the drug, researchers reported March 6 in The New England ...

Doctors are reporting the first advance in three decades in treating kidney complications from lupus, a life-threatening disease that primarily affects young women. A small study showed that an immune ...

FRIDAY, Aug. 8, 2025 (HealthDay News) — Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a spectrum of very different manifestations and variable severity. This makes the ...

A patient audit of more than 1,000 lupus nephritis charts highlights growing experience with biologics and calcineurin inhibitors, alongside rising off-label adoption of SGLT2 inhibitors.Exton, PA, ...